Axial spondyloarthritis (axSpA) is a disease concept entailing the disease entities ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

According to the modified New York criteria, radiographic signs of sacroileitis are mandatory whilst nr-axSpA lack these and is instead, according to the ASAS classification criteria, classified based on imaging with MRI of the sacroiliac joints and/or based on a combination of HLA-B27 positivity in combination with clinical parameters.

However, both AS och nr-axSpA have an equal burden of disease. Patients with nraxSpA failing conventional treatment with at least 2 different NSAIDs and concomitantly having high disease activity are according to EULAR guidelines eligible for biologic treatment. Besides TNF-inhibition, also IL17-inhibition is now indicated for treatment of nraxSpA.

Novartis invites you to a streamed lecture with Lennart Jacobsson, Sr Professor Rheumatology at Sahlgrenska academy, Gothenburg, Sweden and Doctor Giovanni Cagnotto, Skane University Hospital, Malmö, Sweden who was a principal investigator in the PREVENT study, will give a lecture on nr-axSpA and the results from the PREVENT study, studying the efficacy and safety of IL-17A inhibitor, secukinumab in patients with nr-axSpA.


Lecturer:
Sr professor Lennart Jacobsson, Sahlgrenska Academy
Dr Giovanni Cagnotto, Skane University Hospital


Time:
Thursday September 17th at 16:00-17:00 CET


Venue:
Webstreaming from film studio in Malmö.


  • Participation in the meeting requires approval from the head of department.
  • Participation in the meeting is free of costs.
Program 
16:00-16:05
Welcome
Thomas Mandl, Medical Advisor
16:05-16:25
Non-radiographic axial SpA overview
Lennart Jacobsson, Sahlgrenska Academy
16:25-16:45
PREVENT study – Secukinumab in nraxSpA
Giovanni Cagnotto Skane University Hospital
16:45-17:00
Questions and answers
Lennart Jacobsson and Giovanni Cagnotto
SE2006171986 (17 juni 2020)
×

Medical Information Request

×

Ask Speakers

Anmälan 17 september

Genom att anmäla dig till mötet accepterar du att vi behandlar dina uppgifter i enlighet med vår integritetsskyddspolicy.